Basaglar has been approved as a "follow-on" drug based on clinical comparisons with Lantus, the first time a drug has been approved using this pathway. The launch of Basaglar has been co-ordinated ...

We believe that insulin glargine will continue to be widely used ... people living with diabetes and providing support beyond the medicine," said Enrique Conterno, president, Lilly Diabetes.